文献速递肿瘤 PET/CT神经核医学

神经母细胞瘤患者多发性转移:123I-MIBG SPECT/CT完全阴性而68Ga-DOTATATE PET/CT强阳性

Completely Negative 123 I-MIBG SPECT/CT, but Strong Positive 68 Ga-DOTATATE PET/CT of Multiple Metastases in a Neuroblastoma Patient.
PubMed 文献 · Clin Nucl Med · 2025-06-09

一名有神经母细胞瘤病史的6岁男孩在化疗后出现骨髓微小残留病(MRD)阳性,123I-MIBG SPECT/CT未见任何摄取病灶,因MRD阳性且临床高度怀疑复发,随后行68Ga-DOTATATE PET/CT,发现多发性68Ga-DOTATATE高摄取转移灶,组织病理学检查证实为神经母细胞瘤转移,本病例强调在123I-MIBG阴性的患者中,尤其存在潜在复发指征时,68Ga-DOTATATE PET/CT具有补充诊断价值。

要点

  • 6岁神经母细胞瘤男孩化疗后骨髓MRD阳性,123I-MIBG SPECT/CT完全阴性。
  • 因MRD阳性且临床高度怀疑复发,行68Ga-DOTATATE PET/CT发现多发性高摄取转移灶。
  • 组织病理学证实神经母细胞瘤转移,提示68Ga-DOTATATE PET/CT在MIBG阴性时具补充诊断价值。

核心结论

  • 本病例强调在123I-MIBG阴性的患者中,尤其存在潜在复发指征时,68Ga-DOTATATE PET/CT具有补充诊断价值。

研究设计与样本

  • 病例报告:一名有神经母细胞瘤病史的6岁男孩,化疗后出现骨髓微小残留病(MRD)阳性。

主要发现

  • 123I-MIBG SPECT/CT未显示任何高摄取病灶。
  • 因MRD阳性且临床高度怀疑疾病复发,随后行68Ga-DOTATATE PET/CT,发现多发性68Ga-DOTATATE高摄取转移灶。
  • 组织病理学检查证实神经母细胞瘤转移的诊断。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 6-year-old boy with a history of neuroblastoma following chemotherapy presented with positive bone marrow minimal residual disease (MRD). 123 I-MIBG SPECT/CT did not reveal any avid lesions, given the positive MRD and high clinical suspicion for disease recurrence, a subsequent 68 Ga-DOTATATE PET/CT was performed. This modality identified multiple metastatic lesions that were avid for 68 Ga-DOTATATE. Histopathological examination confirmed the diagnosis of neuroblastoma metastasis. This case underscores the complementary diagnostic value of 68 Ga-DOTATATE PET/CT in patients with negative 123I-MIBG findings, particularly when there are indications of potential relapse.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhang K, Li S, Zhou Z, et al. Completely Negative 123 I-MIBG SPECT/CT, but Strong Positive 68 Ga-DOTATATE PET/CT of Multiple Metastases in a Neuroblastoma Patient. Clin Nucl Med. 2025. PMID: 40494383. doi:10.1097/RLU.0000000000006011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。